Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy

CD40 expression correlates with the type I anti-tumor response and better survival. Pan-cancer bioinformatics characterization reveals reduced CD40 expression in 11 cancer types, including RAS(mut) melanoma compared to nevi. RAS mutation correlates with reduced CD40 expression in malignant melanoma....

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Chi, Richmond, Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582157/
https://www.ncbi.nlm.nih.gov/pubmed/34758832
http://dx.doi.org/10.1186/s12943-021-01442-3
Descripción
Sumario:CD40 expression correlates with the type I anti-tumor response and better survival. Pan-cancer bioinformatics characterization reveals reduced CD40 expression in 11 cancer types, including RAS(mut) melanoma compared to nevi. RAS mutation correlates with reduced CD40 expression in malignant melanoma. CD40 expression is associated with better response to immune checkpoint blockade therapy in melanoma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12943-021-01442-3.

Ejemplares similares